NIM
HQL

Nexus Investment Management’s abrdn Life Sciences Investors HQL Stock Holding History

Nexus Investment Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$640 Hold
32
– – ﹤0.01% 72
2026
Q1 		$521 Buy
+32
New +$535 ﹤0.01% 70
2025
Q3 		– Sell
-1,489
Closed -$19.1K – 76
2025
Q2 		$19.1K Hold
1,489
– – ﹤0.01% 75
2025
Q1 		$27.2K Buy
+1,489
New +$20.2K ﹤0.01% 68

Other funds holding HQL

FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
UPS
UHLMANN PRICE SECURITIES Skokie, Illinois $2.68B AUM 149.5% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
ZCP
Z3 Capital Partners Richmond, Virginia $476M AUM
SI
Stephens Inc Little Rock, Arkansas $8.93B AUM 25.13% 1-Year Est. Return
CEFA
Closed-End Fund Advisors Richmond, Virginia $102M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Nexus Investment Management's HQL Position: Q2 2026 in Review

Nexus Investment Management held its abrdn Life Sciences Investors (HQL) position steady in Q2 2026 at 32 shares worth $640. The position accounts for ﹤0.01% of the portfolio, ranked #72.

Nexus Investment Management first reported a position in HQL in Q1 2025 and has held it in 4 quarters since. The position peaked at $27.2K in Q1 2025. 35 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Nexus Investment Management held 32 shares of abrdn Life Sciences Investors worth $640 as of Q2 2026.
  • Nexus Investment Management left its abrdn Life Sciences Investors share count unchanged in Q2 2026.
  • abrdn Life Sciences Investors made up ﹤0.01% of Nexus Investment Management's portfolio in Q2 2026, its #72 holding.
  • Nexus Investment Management first reported a position in abrdn Life Sciences Investors in Q1 2025 and has held it in 4 quarters since.
  • Nexus Investment Management's abrdn Life Sciences Investors position peaked at $27.2K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Nexus Investment Management's 13F filing for Q2 2026, filed 20 Jul 2026.